person · Reporting owner
Struthers Richard Scott
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Frazier Life Sciences Acquisition Corp. IIFLSC · Entity 184069 | Director | October 13, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Frazier Life Sciences Acquisition Corp. II
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-13 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Crinetics Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-01 transaction · row 12
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Disposition to issuer · Disposed 248,043 · Balance 176,663 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 12 · 2026-09-01 · Disposition to issuer · Disposed 176,663 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2026-09-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-01 · Disposition to issuer · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 1 | 0 |
Reported balance
After 2026-09-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-01 · Disposition to issuer · Disposed 136,805 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 2 | 0 |
Reported balance
After 2026-09-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-01 · Disposition to issuer · Disposed 106,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 3 | 0 |
Reported balance
After 2026-09-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-01 · Disposition to issuer · Disposed 110,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 4 | 0 |
Reported balance
After 2026-09-01 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2026-09-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 5 | 0 |
Reported balance
After 2026-09-01 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 6 | 0 |
Reported balance
After 2026-09-01 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 7 | 0 |
Reported balance
After 2026-09-01 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 8 | 0 |
Reported balance
After 2026-09-01 transaction · row 10
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 10 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Charitable Trust | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 11 · 2026-09-01 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.19 · Expires 2029-03-08 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Disposition to issuer · Disposed 172,281 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.61 · Expires 2030-02-24 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-09-01 · Disposition to issuer · Disposed 195,578 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.29 · Expires 2031-02-26 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-09-01 · Disposition to issuer · Disposed 259,058 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2032-02-29 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-09-01 · Disposition to issuer · Disposed 244,205 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2033-02-28 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-09-01 · Disposition to issuer · Disposed 287,700 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.51 · Expires 2034-03-03 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-09-01 · Disposition to issuer · Disposed 240,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.86 · Expires 2035-02-19 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-09-01 · Disposition to issuer · Disposed 313,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.79 · Expires 2036-02-23 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2026-09-01 · Disposition to issuer · Disposed 228,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.
F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 228,000 | $41.21 Strike: $43.79 | $9,395,880.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · derivative · entry 20 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 228,000 shares Expires 2036-02-23 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 313,000 | $48.14 Strike: $36.86 | $15,067,820.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · derivative · entry 19 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 313,000 shares Expires 2035-02-19 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 240,000 | $41.49 Strike: $43.51 | $9,957,600.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · derivative · entry 18 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires 2034-03-03 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 287,700 | $65.36 Strike: $19.64 | $18,804,072.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · derivative · entry 17 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 287,700 shares Expires 2033-02-28 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 244,205 | $64.98 Strike: $20.02 | $15,868,440.90 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · derivative · entry 16 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 244,205 shares Expires 2032-02-29 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 259,058 | $69.71 Strike: $15.29 | $18,058,933.18 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · derivative · entry 15 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 259,058 shares Expires 2031-02-26 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 195,578 | $62.39 Strike: $22.61 | $12,202,111.42 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · derivative · entry 14 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,578 shares Expires 2030-02-24 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 172,281 | $59.81 Strike: $25.19 | $10,304,126.61 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · derivative · entry 13 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 172,281 shares Expires 2029-03-08 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 176,663 | $85.00 | $15,016,355.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 12 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 80,000 | $85.00 | $6,800,000.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 11 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Charitable Trust Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 111,100 | $85.00 | $9,443,500.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 10 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 8 Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 111,100 | $85.00 | $9,443,500.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 9 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 7 Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 111,100 | $85.00 | $9,443,500.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 8 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 6 Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 111,100 | $85.00 | $9,443,500.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 5 Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 100,000 | $85.00 | $8,500,000.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 6 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 4 Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 110,000 | $85.00 | $9,350,000.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 5 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 3 Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 106,000 | $85.00 | $9,010,000.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 4 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 2 Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 136,805 | $85.00 | $11,628,425.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 1 Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 1,000 | $85.00 | $85,000.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 248,043 | $85.00 | $21,083,655.00 |
DisclosureSEC source: 0001628280-26-059882 · wk-form4_1788295965.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,663 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,995 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0001628280-26-055700 · wk-form4_1786479075.xml · derivative · entry 18 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,205 Underlying: Common Stock · 4,995 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,542 | $0.00 Strike: $15.29 | $0.00 |
DisclosureSEC source: 0001628280-26-055700 · wk-form4_1786479075.xml · derivative · entry 17 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,058 Underlying: Common Stock · 6,542 shares Expires 2031-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,422 | $0.00 Strike: $22.61 | $0.00 |
DisclosureSEC source: 0001628280-26-055700 · wk-form4_1786479075.xml · derivative · entry 16 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,578 Underlying: Common Stock · 4,422 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested on March 24, 2020, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,969 | $0.00 Strike: $25.19 | $0.00 |
DisclosureSEC source: 0001628280-26-055700 · wk-form4_1786479075.xml · derivative · entry 15 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,281 Underlying: Common Stock · 3,969 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the shares subject to the option vested monthly. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 4,995 | $20.02 | $99,999.90 |
DisclosureSEC source: 0001628280-26-055700 · wk-form4_1786479075.xml · nonDerivative · entry 4 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 6,542 | $15.29 | $100,027.18 |
DisclosureSEC source: 0001628280-26-055700 · wk-form4_1786479075.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 4,422 | $22.61 | $99,981.42 |
DisclosureSEC source: 0001628280-26-055700 · wk-form4_1786479075.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 413,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 3,969 | $25.19 | $99,979.11 |
DisclosureSEC source: 0001628280-26-055700 · wk-form4_1786479075.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 111,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 14 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 8 Disclosed balance after: 111,100 F3 · kind: (3) Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 111,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 13 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 7 Disclosed balance after: 111,100 F3 · kind: (3) Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 111,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 12 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,000 F3 · kind: (3) Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 111,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 11 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 112,100 F3 · kind: (3) Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 111,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 10 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 6 Disclosed balance after: 111,100 F2 · kind: (2) Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 111,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 9 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 5 Disclosed balance after: 111,100 F2 · kind: (2) Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 111,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 8 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,778 F2 · kind: (2) Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 111,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515,878 F2 · kind: (2) Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 6 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Charitable Trust Disclosed balance after: 80,000 F1 · kind: (1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 222,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 5 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 223,200 F1 · kind: (1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 222,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 4 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 626,978 F1 · kind: (1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 1 Disclosed balance after: 136,805 F1 · kind: (1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 222,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 1 Disclosed balance after: 216,805 F1 · kind: (1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 222,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039784 · wk-form4_1780430656.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 1 Disclosed balance after: 439,005 F1 · kind: (1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:05 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 8,785 | $37.77 | $331,809.45 |
DisclosureSEC source: 0001628280-26-019488 · wk-form4_1773867929.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 404,778 F1 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:05 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 13,196 | $37.11 | $489,703.56 |
DisclosureSEC source: 0001628280-26-019488 · wk-form4_1773867929.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 413,563 F1 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:37 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (Right to Buy) · Derivative | 228,000 | $0.00 Strike: $43.79 | $0.00 |
DisclosureSEC source: 0001628280-26-011730 · wk-form4_1772055418.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,000 Underlying: Common Stock · 228,000 shares Expires 2036-02-23 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:37 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011730 · wk-form4_1772055418.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,759 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 23:54 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,400 | $0.00 Strike: $15.29 | $0.00 |
DisclosureSEC source: 0001628280-25-058056 · wk-form4_1766102083.xml · derivative · entry 9 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,058 Underlying: Common Stock · 28,400 shares Expires 2031-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 23:54 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,342 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001628280-25-058056 · wk-form4_1766102083.xml · derivative · entry 8 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,342 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 23:54 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 28,400 | $15.29 | $434,236.00 |
DisclosureSEC source: 0001628280-25-058056 · wk-form4_1766102083.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 23:54 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 16,342 | $9.28 | $151,653.76 |
DisclosureSEC source: 0001628280-25-058056 · wk-form4_1766102083.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.